How to Test for GHB: An Overview of Detection Methods

Detecting GHB (gamma-hydroxybutyric acid) is uniquely difficult because the drug is cleared from blood and urine within hours and because the human body produces small amounts of GHB on its own. Those two facts shape every testing method available, from emergency-room screening to forensic hair analysis to the drink-testing strips sold in bars. The result is a patchwork of approaches, each suited to a different scenario and time frame, and none of them foolproof.

Why GHB Is So Hard to Detect

GHB occurs naturally in the body at trace levels, roughly 0.5 to 1.0 mg/L in various tissues including the brain, where it acts as both a building block and a breakdown product of GABA, the brain’s main calming neurotransmitter.¹ That baseline presence means any test has to distinguish between the GHB your body made and the GHB someone swallowed or was given. Labs handle this by setting cutoff concentrations: a result has to exceed a certain threshold before it counts as positive. One large dataset found that background GHB in serum ranged up to about 3 mg/L, leading researchers to recommend a cutoff of 4 mg/L in living patients’ serum and 6 mg/L in urine.² These cutoffs are different for different specimen types and for living versus deceased individuals, which already hints at how tricky interpretation can be.³

The other major obstacle is speed. GHB has an extremely short elimination half-life. In most adults, urine samples taken more than about 12 hours after ingestion no longer show GHB above the cutoff.⁴ Blood clears even faster. That means a person who wakes up the morning after being drugged may already be past the window for a standard urine test. Getting a sample as early as possible is the single most important step in confirming GHB exposure.

Detection Windows by Specimen Type

Different body fluids offer different windows, and none of them are long. In blood, GHB concentrations drop below detectable levels within roughly four to eight hours of ingestion. Urine is somewhat more forgiving, with a commonly cited window of about 12 hours, though one case report documented a positive urine result more than 24 hours after ingestion in an elderly woman who likely received a large dose.⁴ Factors like age, kidney function, and the amount consumed can all push that window slightly wider or narrower.

Oral fluid (saliva) has attracted interest as a non-invasive sample, but its detection window is even shorter. A placebo-controlled clinical trial found that GHB levels in oral fluid were clearly elevated above placebo for only about four hours. Using a cutoff of 5 micrograms per milliliter, only 40 percent of participants exceeded the threshold at two hours after dosing, and none did at six hours.⁵ In practice, saliva testing for GHB is still largely a research tool rather than a reliable clinical option.

Hair stands apart from every other specimen. Because GHB incorporates into the hair shaft as it grows, hair analysis can potentially look back weeks or months. But hair testing for GHB comes with its own challenge: endogenous GHB also ends up in hair, so distinguishing a baseline signal from drug exposure requires careful comparison. Researchers have developed methods that cut single hairs into tiny 2-millimeter segments and measure GHB in each one, looking for spikes that stand out from the person’s own baseline. In one case, reproducible concentration peaks along the hair shaft pointed to external GHB ingestion.⁶ This technique is promising but still early-stage, and results need further verification before they carry routine forensic weight.

Emergency Room and Clinical Screening

When a patient arrives at an emergency department unconscious or confused and GHB exposure is suspected, speed matters more than perfection. Standard hospital drug screens — the kind that check for opioids, benzodiazepines, and amphetamines — do not include GHB. A separate, dedicated test is needed.

Automated enzymatic assays have been developed to fill this gap. These tests work on the same clinical chemistry analyzers hospitals already use, producing a quantitative GHB result in serum or urine within minutes.⁷ One hospital trialed a novel enzymatic system in its emergency department over a three-month period to measure GHB in blood and urine of patients suspected of being intoxicated.⁸ The advantage is immediacy: the result can guide treatment decisions while the patient is still in the ER. The limitation is that enzymatic assays are screening tools. A positive result is useful for clinical management, but if the case might end up in court, a confirmatory test using a more specific method is typically required.

Confirmatory Laboratory Methods

For forensic and legal purposes, the gold-standard approaches use gas chromatography paired with mass spectrometry (GC-MS) or liquid chromatography paired with tandem mass spectrometry (LC-MS/MS). These instruments separate GHB from everything else in a sample and then identify it by its molecular fingerprint, making false positives extremely unlikely.

GC-MS has been the workhorse of forensic GHB testing for years. One validated forensic method using GC-MS with tandem mass spectrometry achieved a detection limit of 0.1 mg/L in whole blood — well below the cutoffs used to flag exogenous exposure — with a working range up to 100 mg/L.⁹ GC-MS has also been validated for hair samples, where overnight chemical extraction followed by derivatization allows the instrument to pick up GHB at very low concentrations.¹⁰

LC-MS/MS methods have gained ground because they can often skip the derivatization step that GC-MS requires, simplifying sample preparation. LC-MS/MS methods have been developed for blood, urine, and oral fluid, including at the very low endogenous concentration range.¹¹ A specialized approach using what researchers call a “surrogate analyte” technique improves accuracy for urine measurements by accounting for the fact that GHB is already present in every urine sample before any drug exposure.¹²

Novel Biomarkers That Extend the Detection Window

The 12-hour urine window has long been the central frustration of GHB forensics. Researchers have been hunting for metabolites — breakdown products — that linger in the body longer than GHB itself. Recent metabolomics work has identified several GHB conjugates, molecules formed when the body attaches GHB to amino acids or other compounds. These include GHB-glycine, GHB-taurine, GHB-glutamate, GHB-carnitine, and GHB-pentose.

Not all of these markers are equally useful. Most of the amino acid conjugates decline almost as fast as GHB itself, with urinary half-lives around one to two hours.¹³ GHB-pentose stands out: it declines more slowly, with a half-life of about 2.4 hours, and its urinary levels remain relatively high even eight hours after ingestion, making it the most promising candidate for extending the detection window among the conjugates studied so far.¹⁴ GHB-glycine has also shown strong discriminatory potential, with one review noting it could push the detection window out to about 28 hours.¹⁵

These biomarkers are not yet part of routine forensic testing. The methods for measuring them require high-resolution mass spectrometry and have mostly been validated in research settings. But they represent the most promising frontier for closing the gap between when GHB is used and when it can still be detected.

Testing Drinks Before Consumption

A separate category of GHB detection focuses on beverages rather than body fluids — the goal being to catch the drug before someone drinks it. Several commercial products exist, including test strips, coasters, and cards designed for use in bars and social settings. The technology behind them varies, and so does their reliability.

First-generation drink test strips typically rely on bromocresol green, a pH-sensitive dye. A lab evaluation of six such products found that two were completely insensitive to GHB even at very high concentrations. The remaining first-generation strips produced positive results only at concentrations between 3.2 and 16 mg/mL. Colored drinks like beer, wine, and whiskey produced interfering colors that made results hard to read. Second-generation strips use an enzyme specific to GHB (gamma-hydroxybutyric dehydrogenase) and performed substantially better, detecting GHB at 0.5 mg/mL and producing clearer results across a range of drink types.¹⁶

Researchers have also developed colorimetric paper sensors that change from blue to red in the presence of GHB-spiked drinks, with detection limits low enough to flag dangerous concentrations and the ability to work in both alcoholic and colored beverages.¹⁷ Another approach uses a lateral-flow strip combined with a smartphone camera and a small 3D-printed case containing an LED light. After about 60 seconds of development, the strip’s fluorescence is read by the phone, and the system can identify GHB in both alcoholic and soft drinks without trained personnel.¹⁸

Perhaps the most eye-catching prototype is a wearable sensor designed as a strip affixed to a fingernail. The wearer dips a finger into a drink; in the presence of GHB, a chemical reaction causes the strip to change from orange to colorless within 15 minutes.¹⁹ These devices are still in the research phase, but they point to a future where GHB detection in social settings could be much more discreet than pulling out a test strip.

Testing for GHB’s Precursors in Beverages

GHB is not the only substance to worry about in spiking scenarios. Two precursor chemicals — gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) — convert to GHB inside the body after ingestion. Both are legally available industrial solvents, which makes them easier to obtain than GHB itself in many jurisdictions.²⁰ A drink test that catches GHB but misses GBL and 1,4-BD leaves a significant gap.

Laboratory methods using LC-MS/MS can detect all three compounds simultaneously in beverages. One validated method tested GHB, GBL, and 1,4-BD in carbonated drinks, tea, apple cider vinegar, and coffee, achieving detection limits of 0.2 micrograms per milliliter for GBL and 0.5 for GHB and 1,4-BD, with recoveries between 90 and 110 percent across all four drink types.²¹ These methods are reliable but require lab equipment. Most consumer-grade test strips do not detect GBL or 1,4-BD, which is a limitation worth knowing about.

Post-Mortem Complications

When GHB testing enters death investigations, an entirely different set of problems appears. After death, bacteria in decomposing tissue can produce GHB on their own, causing concentrations to rise in stored samples. One study found that mean GHB concentrations in post-mortem blood were above 12 mg/L — well above the cutoff for living patients — even in cases where GHB exposure may not have occurred.²² In other words, a dead person’s blood can test “positive” for GHB purely as an artifact of decomposition.

Storage conditions make a big difference. In post-mortem blood stored at room temperature, GHB concentrations can rise dramatically over 30 days. Refrigeration at 4°C slows the increase, and the addition of sodium fluoride as a preservative reduces it further. Vitreous humor (the fluid inside the eye) tends to be more stable and is sometimes preferred for post-mortem GHB interpretation.²³ Long-term studies have shown that in samples from living subjects stored at minus 20°C with fluoride preservative, GHB concentrations remain fairly stable for years, with an average change of less than one percent. Post-mortem samples are less predictable, with a mean shift of about minus seven percent but individual samples varying by as much as 34 percent in either direction.²⁴ The takeaway for forensic pathologists is that specimen type, preservative use, storage temperature, and time since death all have to be weighed alongside the measured concentration.

Advanced Sensor Chemistry

Beyond the strip tests aimed at bar patrons, chemists have been developing more sophisticated optical sensors for GHB. One system uses a pair of specially designed molecular probes that, together, produce both a visible yellow color and blue fluorescence when GHB is present. The sensitivity reported is remarkably high — down to about 0.6 nanograms per milliliter — with a response time of just 0.2 seconds, and the system correctly ignores 22 other substances that might be present in a drink.²⁵ Another approach, called GHB Orange, was among the first fluorescent sensors designed specifically for GHB and works by detecting fluorescence quenching when the drug binds to the sensor molecule.²⁶

A silica-based optical sensor designed for oral fluid detection can produce a visible pink color in the presence of GHB, detectable by the naked eye. Its sensitivity falls within the range of endogenous GHB levels in saliva, meaning any concentration significantly above that baseline could signal external exposure.²⁷ None of these sensors are commercially available for consumers yet, but they illustrate a clear direction: GHB detection is moving toward faster, cheaper, more portable devices that a non-expert can use.

When Elevated GHB Is Not From Drug Exposure

There is at least one medical condition that produces genuinely elevated GHB levels without any drug being taken. Succinic semialdehyde dehydrogenase deficiency, or SSADHD, is a rare inherited metabolic disorder in which the enzyme responsible for breaking down a GHB precursor does not work properly. The result is that both GABA and GHB accumulate to levels well above what is normal.²⁸ People with SSADHD — mostly diagnosed in childhood — can have persistently elevated GHB in blood and urine that has nothing to do with drug use. While the condition is rare enough that it will almost never complicate a forensic case, clinicians and toxicologists are aware of it as a potential confound.

Population-Level Monitoring Through Wastewater

Individual testing is not the only way to track GHB use. Researchers have explored wastewater-based epidemiology, where sewage samples are analyzed for drug residues to estimate consumption patterns across entire communities. A study published in JAMA Network Open noted that wastewater monitoring of various substances offers a complementary tool to existing public health surveillance, providing timely data on substance use at the population level.²⁹ For GHB specifically, the short biological half-life that frustrates individual testing is less of a problem at the sewage-plant scale, where the collective signal of an entire city’s GHB consumption can be captured in a single sample. This approach is not useful for identifying individuals but can alert public health agencies to rising or falling GHB use in a region faster than hospital admission data or survey-based estimates.

Practical Guidance for Suspected Exposure

If you suspect someone has been drugged with GHB, the most important thing is timing. Blood and urine samples should be collected as soon as possible — ideally within a few hours. Ask the hospital or clinic specifically to test for GHB, because it will not show up on a standard drug panel. If a urine sample can be collected early, even before arriving at a hospital, sealing it in a clean container and refrigerating it can help preserve it for later testing.

For drink testing, be aware of the limitations of available commercial products. First-generation test strips based on pH-indicator dyes have high failure rates and are easily confused by dark or acidic drinks. Enzyme-based second-generation products are substantially better but still not foolproof. No consumer drink test currently detects GBL or 1,4-BD, the two precursor chemicals that convert to GHB in the body.

For forensic cases involving hair analysis, you do not need to rush. Hair testing works on a time scale of weeks to months, so it can fill in gaps that blood and urine testing missed. But it requires a specialized laboratory, and results need to be interpreted against a person’s individual endogenous baseline, which makes the analysis more complex and more expensive than a standard toxicology screen. Requesting hair analysis is most useful when significant time has passed since the suspected exposure and other specimens are no longer viable.